Xpert Xpress CoV-2/Flu plus
Cepheid · Decision date Oct 2, 2026
What did the FDA decide?
Cepheid received a substantially equivalent determination for the Xpert Xpress CoV-2/Flu plus under 510(k) K263120, with a decision date of 10/02/2026 and a receipt date of 09/04/2026. The device falls under product code QOF (Class II, 21 CFR 866.3981, Microbiology panel), with subsequent product code OOI (21 CFR 862.2570, Clinical Chemistry panel). The FDA decision summary describes the submission as covering modifications to Cepheid's own previously cleared Class II device.
The recorded change was a software modification to mask an analyte; the summary states that no new performance data were reviewed and that the indications for use and fundamental scientific technology were unchanged. CLIA records list the Xpert Xpress CoV-2/Flu plus on the GeneXpert Dx and GeneXpert Infinity systems for Influenza A/B and SARS-CoV-2 at moderate complexity, effective 10/09/2026. The specific analyte masked, the predicate device's 510(k) number, and any performance characteristics are not stated in the available excerpts.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263120
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Cepheid
- Product code
- QOF
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.
FDA decision timeline
K263120 received
Application receipt date recorded by FDA.
K263120 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| GenMark Diagnostics, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
Xpert Xpress CoV-2/Flu plusK263333 | Cepheid | 510(k) clearance | Oct 22, 2026 | FDA |
Xpert Respiratory PanelK261336 | Cepheid | 510(k) clearance | Sep 25, 2026 | FDA |
| Biofire Diagnostics | 510(k) clearance | Sep 22, 2026 | FDA | |
| Baebies, Inc. | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cepheid
- Headquarters
- Not reported
- Brand website
- cepheid.com
- FDA applicant address
- Sunnyvale, CA
Sources and methodology
- Original FDA record: K263120
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


